NO327358B1 - Anvendelse av en kombinasjon for behandling av proliferative sykdommer - Google Patents
Anvendelse av en kombinasjon for behandling av proliferative sykdommer Download PDFInfo
- Publication number
- NO327358B1 NO327358B1 NO20040973A NO20040973A NO327358B1 NO 327358 B1 NO327358 B1 NO 327358B1 NO 20040973 A NO20040973 A NO 20040973A NO 20040973 A NO20040973 A NO 20040973A NO 327358 B1 NO327358 B1 NO 327358B1
- Authority
- NO
- Norway
- Prior art keywords
- day
- phthalazine
- pyridylmethyl
- dose
- administered
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 20
- 201000010099 disease Diseases 0.000 title claims description 16
- 238000011282 treatment Methods 0.000 title claims description 13
- 230000002062 proliferating effect Effects 0.000 title claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 26
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 229960002949 fluorouracil Drugs 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 abstract description 6
- WHOWNXIYXLWMGJ-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)phthalazine Chemical compound N=1N=CC2=CC=CC=C2C=1CC1=CC=NC=C1 WHOWNXIYXLWMGJ-UHFFFAOYSA-N 0.000 abstract description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract description 4
- 206010038389 Renal cancer Diseases 0.000 abstract description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract description 2
- 201000010982 kidney cancer Diseases 0.000 abstract description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 201000010174 renal carcinoma Diseases 0.000 abstract 1
- 230000009467 reduction Effects 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000013535 dynamic contrast enhanced MRI Methods 0.000 description 6
- 208000037821 progressive disease Diseases 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 230000004044 response Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 206010007270 Carcinoid syndrome Diseases 0.000 description 3
- 208000002458 carcinoid tumor Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- -1 2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6- pteridinyl Chemical group 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000006510 metastatic growth Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 description 2
- LPJXPACOXRZCCP-VIFPVBQESA-N (2s)-2-benzamidopentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 LPJXPACOXRZCCP-VIFPVBQESA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002322 enterochromaffin cell Anatomy 0.000 description 1
- 238000012057 exposure response modelling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33102501P | 2001-09-12 | 2001-09-12 | |
US31869401P | 2001-09-12 | 2001-09-12 | |
US32204401P | 2001-09-14 | 2001-09-14 | |
US38816302P | 2002-06-12 | 2002-06-12 | |
PCT/EP2002/010194 WO2003022282A1 (en) | 2001-09-12 | 2002-09-11 | Use of 4-pyridylmethylphthalazines for cancer treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20040973L NO20040973L (no) | 2004-06-03 |
NO327358B1 true NO327358B1 (no) | 2009-06-15 |
Family
ID=27502161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20040973A NO327358B1 (no) | 2001-09-12 | 2004-03-05 | Anvendelse av en kombinasjon for behandling av proliferative sykdommer |
Country Status (22)
Country | Link |
---|---|
US (2) | US20040258770A1 (zh) |
EP (1) | EP1427420B1 (zh) |
JP (1) | JP2005502690A (zh) |
KR (1) | KR20040029172A (zh) |
CN (1) | CN1330308C (zh) |
AT (2) | ATE329597T1 (zh) |
AU (2) | AU2002342678B2 (zh) |
BR (1) | BR0212446A (zh) |
CA (1) | CA2457848A1 (zh) |
CO (1) | CO5560545A2 (zh) |
CY (1) | CY1105189T1 (zh) |
DE (2) | DE60231068D1 (zh) |
DK (1) | DK1427420T3 (zh) |
ES (2) | ES2320922T3 (zh) |
HR (1) | HRP20040241A2 (zh) |
IL (1) | IL160382A0 (zh) |
NO (1) | NO327358B1 (zh) |
NZ (1) | NZ531484A (zh) |
PL (1) | PL367349A1 (zh) |
PT (1) | PT1427420E (zh) |
RS (1) | RS16804A (zh) |
WO (1) | WO2003022282A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0223341D0 (en) * | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
EP1738752A1 (en) * | 2002-12-27 | 2007-01-03 | Schering Aktiengesellschaft | Pharmaceutical combinations comprising cis-retine acid |
WO2004105747A1 (en) * | 2003-05-20 | 2004-12-09 | Aronex Pharmaceuticals, Inc | Combination chemotherapy comprising capecitabine and a liposomal platinum complex |
JP2007505938A (ja) * | 2003-09-23 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Vegf受容体阻害剤と化学療法剤の組み合わせ |
GB0610925D0 (en) * | 2006-06-02 | 2006-07-12 | Novartis Ag | Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer |
KR101037292B1 (ko) * | 2010-09-03 | 2011-05-27 | (주)슈추어 | 신발 장식구 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849741A (en) * | 1994-08-09 | 1998-12-15 | Eisai Co., Ltd. | Fused pyridazine compounds |
NZ331191A (en) * | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
US6096904A (en) * | 1996-12-03 | 2000-08-01 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
-
2002
- 2002-09-11 DE DE60231068T patent/DE60231068D1/de not_active Expired - Lifetime
- 2002-09-11 BR BR0212446-7A patent/BR0212446A/pt not_active IP Right Cessation
- 2002-09-11 US US10/489,751 patent/US20040258770A1/en not_active Abandoned
- 2002-09-11 JP JP2003526411A patent/JP2005502690A/ja active Pending
- 2002-09-11 ES ES06114903T patent/ES2320922T3/es not_active Expired - Lifetime
- 2002-09-11 PL PL02367349A patent/PL367349A1/xx not_active Application Discontinuation
- 2002-09-11 EP EP02779338A patent/EP1427420B1/en not_active Expired - Lifetime
- 2002-09-11 DE DE60212415T patent/DE60212415T2/de not_active Expired - Lifetime
- 2002-09-11 KR KR10-2004-7003645A patent/KR20040029172A/ko active IP Right Grant
- 2002-09-11 WO PCT/EP2002/010194 patent/WO2003022282A1/en active Application Filing
- 2002-09-11 CN CNB028178831A patent/CN1330308C/zh not_active Expired - Fee Related
- 2002-09-11 AT AT02779338T patent/ATE329597T1/de not_active IP Right Cessation
- 2002-09-11 IL IL16038202A patent/IL160382A0/xx not_active IP Right Cessation
- 2002-09-11 AT AT06114903T patent/ATE421880T1/de not_active IP Right Cessation
- 2002-09-11 AU AU2002342678A patent/AU2002342678B2/en not_active Ceased
- 2002-09-11 CA CA002457848A patent/CA2457848A1/en not_active Abandoned
- 2002-09-11 RS YUP-168/04A patent/RS16804A/sr unknown
- 2002-09-11 ES ES02779338T patent/ES2266590T3/es not_active Expired - Lifetime
- 2002-09-11 DK DK02779338T patent/DK1427420T3/da active
- 2002-09-11 PT PT02779338T patent/PT1427420E/pt unknown
- 2002-09-11 NZ NZ531484A patent/NZ531484A/en not_active IP Right Cessation
-
2004
- 2004-02-27 CO CO04017661A patent/CO5560545A2/es active IP Right Grant
- 2004-03-05 NO NO20040973A patent/NO327358B1/no not_active IP Right Cessation
- 2004-03-11 HR HR20040241A patent/HRP20040241A2/hr not_active Application Discontinuation
-
2006
- 2006-08-09 AU AU2006203428A patent/AU2006203428B2/en not_active Ceased
- 2006-08-31 CY CY20061101239T patent/CY1105189T1/el unknown
-
2009
- 2009-04-15 US US12/423,843 patent/US20090196871A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040258770A1 (en) | 2004-12-23 |
DE60212415T2 (de) | 2006-11-23 |
PL367349A1 (en) | 2005-02-21 |
ES2320922T3 (es) | 2009-05-29 |
JP2005502690A (ja) | 2005-01-27 |
BR0212446A (pt) | 2004-08-17 |
KR20040029172A (ko) | 2004-04-03 |
WO2003022282A1 (en) | 2003-03-20 |
RS16804A (en) | 2007-02-05 |
DE60212415D1 (de) | 2006-07-27 |
CN1553803A (zh) | 2004-12-08 |
AU2002342678B2 (en) | 2006-08-24 |
US20090196871A1 (en) | 2009-08-06 |
ATE421880T1 (de) | 2009-02-15 |
EP1427420B1 (en) | 2006-06-14 |
CN1330308C (zh) | 2007-08-08 |
ES2266590T3 (es) | 2007-03-01 |
ATE329597T1 (de) | 2006-07-15 |
EP1427420A1 (en) | 2004-06-16 |
NO20040973L (no) | 2004-06-03 |
AU2006203428A1 (en) | 2006-08-31 |
CO5560545A2 (es) | 2005-09-30 |
DK1427420T3 (da) | 2006-10-02 |
DE60231068D1 (de) | 2009-03-19 |
CA2457848A1 (en) | 2003-03-20 |
IL160382A0 (en) | 2004-07-25 |
PT1427420E (pt) | 2006-10-31 |
CY1105189T1 (el) | 2010-03-03 |
HRP20040241A2 (en) | 2005-04-30 |
AU2006203428B2 (en) | 2009-06-04 |
NZ531484A (en) | 2007-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012515184A (ja) | 大腸がんの治療方法 | |
BRPI0915284B1 (pt) | composição farmacêutica oral, e, uso de uma composição farmacêutica | |
WO2019109938A1 (zh) | Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途 | |
CN107635547A (zh) | 用于治疗和预防肿瘤的甲苯哒唑多形体 | |
JP2021502415A (ja) | 癌の処置のためのアパチニブを用いる併用療法 | |
JP2023102787A (ja) | 癌の治療におけるドセタキセルの長期使用 | |
TW202402290A (zh) | 癌症治療 | |
CN109803684B (zh) | 用于治疗肝细胞癌的组合疗法 | |
JP2022514960A (ja) | ドセタキセルおよびcyp3a阻害剤を用いる固形腫瘍の組み合わせ治療 | |
AU2006203428B2 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
Mehnert et al. | A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors | |
TWI771344B (zh) | 一種vegfr抑制劑與parp抑制劑聯合在製備治療胃癌的藥物中的用途 | |
US20230321110A1 (en) | Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma | |
JP2022160654A (ja) | 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ | |
TWI814703B (zh) | 供癌症醫療的節拍式口服吉西他賓 | |
CN115135326A (zh) | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 | |
AU2002342678A1 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
EP1712234B1 (en) | Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment | |
WO2023155182A1 (zh) | 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用 | |
Jones et al. | A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non–small-cell lung cancer | |
RU2320344C2 (ru) | Применение 4-пиридилметилфталазинов для лечения рака | |
Wang et al. | Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma | |
JP2023099919A (ja) | 進行した転移性がんの治療 | |
JP2024531653A (ja) | 固形腫瘍の処置のための経口投与パクリタキセル、P-gp阻害剤、およびチェックポイント阻害剤の治療的組み合わせ | |
WO2024023766A1 (en) | P13k inhibitor combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |